Clinical Trial

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen PsA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.
Protocol Amendment History 7 changes
notable Trial sites expanded: 46 -> 50 locations 2026-08-11
notable Trial sites expanded: 38 -> 41 locations 2026-06-09
notable Trial sites expanded: 28 -> 38 locations 2026-06-02
notable Trial sites expanded: 6 -> 28 locations 2026-05-27
critical Recruitment opened 2026-04-28
critical Primary endpoint(s) modified 2026-04-28
notable Trial sites expanded: 0 -> 4 locations 2026-04-28
Trial Details
NCT Number NCT07486960
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Psoriatic Arthritis
Enrollment 140 participants
Start Date 2026-04-20
Primary Completion 2027-08-13 (estimated)
Study Completion 2030-01-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-10